Axsome Therapeutics (AXSM) Cash from Operations (2015 - 2026)
Axsome Therapeutics (AXSM) posted Cash from Operations of 20700000.0 for Q1 2026, down 10.97% sequentially from 18653000.0 in Q4 2025, and up 52.28% YoY from 13593679.03 in Q1 2025.
Powered by 
Analysis
Axsome Therapeutics (AXSM) Cash from Operations (2015 - 2026) Analysis & Trends
Axsome Therapeutics has reported Cash from Operations for 12 years, with the latest figure at 20700000.0 in Q1 2026.
- Quarterly Cash from Operations rose 52.28% year-over-year to 20700000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 70730000.0 (up 40.22% YoY) and the FY2025 annual result came in at 93405000.0, up 27.26% from the prior year.
- Cash from Operations fell to 20700000.0 in Q1 2026 per AXSM's latest filing, from 18653000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1046000.0 in Q3 2025 and troughed at 55349000.0 in Q2 2023.
- A 5-year average of 29653294.12 and a median of 30110000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations sank 818.52% in 2024, then surged 105.61% in 2025.
- Over 5 years, Cash from Operations stood at 27563000.0 in 2022, then decreased by 10.15% to 30362000.0 in 2023, then increased by 13.7% to 26202000.0 in 2024, then rose by 28.81% to 18653000.0 in 2025, then fell by 10.97% to 20700000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 20700000.0, 18653000.0, and 1046000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Axsome Therapeutics | 10.75 Bn | 10.43 Bn | 204.81 Mn | -32.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.95 Mn |
| Mar 31, 2026 | -20.70 Mn |
| Dec 31, 2025 | -18.65 Mn |
| Sep 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | -32.42 Mn |
| Mar 31, 2025 | -43.38 Mn |
| Dec 31, 2024 | -26.20 Mn |
| Sep 30, 2024 | -18.63 Mn |
| Jun 30, 2024 | -30.11 Mn |
| Mar 31, 2024 | -53.47 Mn |
| Dec 31, 2023 | -30.36 Mn |
| Sep 30, 2023 | -53.55 Mn |
| Jun 30, 2023 | -55.35 Mn |
| Mar 31, 2023 | -5.82 Mn |
| Dec 31, 2022 | -27.56 Mn |
| Sep 30, 2022 | -22.76 Mn |
| Jun 30, 2022 | -33.54 Mn |
| Mar 31, 2022 | -32.65 Mn |
| Dec 31, 2021 | -28.84 Mn |
| Sep 30, 2021 | -26.78 Mn |